Browse Related Topics For:

Generic Drugs The United States Food and Drug Administration

179
Pharmaceutical Industry
101
Pharmaceutical Patents
97
Prescription Drugs
88
ANDA
88
Patents
75
Patent Infringement
74
Hatch-Waxman
63
Patent Litigation
37
Biosimilars
29
SCOTUS
25
Preemption
24
Labeling
23
BPCIA
21
FDCA
19
Patent-in-Suit
17
Medical Devices
17
Sandoz
16
FTC
15
Amgen
15
Apotex
15
Failure To Warn
14
Appeals
14
Popular
13
Biologics
13
Manufacturers
12
Antitrust Litigation
12
Commercial Marketing
12
FDA Approval
12
Healthcare
12
Reverse Payment Settlement Agreements
11
Mylan Pharmaceuticals
11
PLIVA v Mensing
10
Patent Dance
10
Sandoz v Amgen
10
Teva Pharmaceuticals
10
Warning Labels
9
Affordable Care Act
9
FTC v Actavis
8
Orange Book
8
Preliminary Injunctions
8
Product Exclusivity
7
Actavis Inc.
7
Class Action
7
Corporate Counsel
7
Drug Pricing
7
Notice Requirements
7
Orphan Drugs
7
Patent Applications
7
Personal Jurisdiction
7
Prior Art
6
Declaratory Judgments
6
Draft Guidance
6
Life Sciences
6
Medicare
6
Product Hopping
6
Sherman Act
6
Summary Judgment
6
USPTO
6
Watson Pharmaceuticals
5
aBLA
5
Antitrust Violations
5
Biologics Price Competition and Innovation Act of 2009
5
HHS
5
Intellectual Property Protection
5
Medicaid
5
Mutual Pharmaceuticals v Bartlett
5
Otsuka Pharmaceutical
5
Product Labels
5
Proposed Regulation
5
Safe Harbors
4
Amarin
4
Anti-Competitive
4
CMS
4
Design Defects
4
DOJ
4
Endo Pharmaceuticals
4
Exclusivity
4
GlaxoSmithKline
4
Jurisdiction
4
Monopolization
4
No-AG Agreement
4
OIG
4
On-Sale Bar
4
Pay-For-Delay
4
Proposed Legislation
4
REMS
3
21st Century Cures Initiative
3
AbbVie
3
Allergan Inc
3
Antitrust Provisions
3
AstraZeneca
3
Bayer
3
Brand
3
Citizen Petitions
3
Classen Immunotherapies
3
Comment Period
3
Competition
3
Congressional Investigations & Hearings
3
Drug Safety
3
Elan Pharmaceuticals
3
Eli Lilly
3
Federal Rule 12(b)(6)
3
GDUFA
3
Health Care Providers
3
Healthcare Reform
3
Hospira
3
Hospitals
3
Inter Partes Review (IPR) Proceeding
3
Learned Intermediary
3
Licensing Rules
3
Medicare Part B
3
Merck
3
Multidistrict Litigation
3
Off-Label Promotion
3
Patent Invalidity
3
Pharmacies
3
Pleading Standards
3
Professional Conferences
3
Public Health Service Act
3
Rule-of-Reason Analysis
3
Rulemaking Process
3
Spectrum
3
Standing
3
Takeda Pharmaceuticals
3
Telehealth
3
Trademarks
3
Trump Administration
2
Allergan v Sandoz
2
America Invents Act
2
Antitrust Injuries
2
Biotechnology
2
Canada
2
Cancer
2
Causation
2
CDC
2
Cephalon
2
Chevron Deference
2
China
2
Class Certification
2
Clinical Trials
2
Co-Op
2
Congressional Committees
2
Contraceptive Coverage Mandate
2
DaimlerAG
2
DaimlerChrysler v Bauman
2
Dismissals
2
Drug Compounding
2
Durable Medical Equipment
2
Duty to Deal
2
E-Cigarettes
2
Enforcement Actions
2
EU
2
False Advertising
2
False Claims Act (FCA)
2
First Amendment
2
Food Safety
2
Foreign Manufacturers
2
Free Speech
2
General Jurisdiction
2
Health Information Technologies
2
Induced Infringement
2
Injunctive Relief
2
Innovator Liability
2
Intellectual Property Litigation
2
INTERPOL
2
Legislative Agendas
2
Medicare Part D
2
Medicare Prescription Drug Improvement and Modernization Act (MMA)
2
MedPAC
2
Medtronic
2
Mensing
2
Mental Health
2
Motion to Dismiss
2
Motion To Stay
2
NIH
2
Obviousness
2
Off-Label Use
2
Permanent Injunctions
2
PHRMA
2
Product Defects
2
Putative Class Actions
2
Rebates
2
Roxane Laboratories
2
SEC
2
SNDAs
2
Substance Abuse
2
Suppliers
2
Telemedicine
2
Transfer of Venue
2
TRO
2
Twombly/Iqbal Pleading Standard
2
Unfair Competition
2
Websites
2
Wyeth
1
35 U.S.C. § 271(e)(1)
1
3D Printing
1
510(k) RTA
1
Abbott Laboratories
1
ACOs
1
Actos
1
Advance Notice
1
Alternative Payment Models (APM)
1
Amended Complaints
1
Amended Regulation
1
Anti-Monopoly
1
Antibiotics
1
Antitrust Conspiracies
1
App Developers
1
Attorney Generals
1
Australia
1
Automatic Enrollment
1
Barack Obama
1
Best Practices
1
Bifurcation
1
Biopharmaceutical
1
Bipolar Disorder
1
Boehringer
1
Books
1
BPCI
1
Burden of Proof
1
CA Supreme Court
1
Cadillac Tax
1
CAFC
1
Cartwright Act
1
Carve Out Provisions
1
Center for Drug Evaluation and Research (CDER)
1
Cipro
1
Civil Monetary Penalty
1
Claim Construction
1
Clearance
1
CLIA
1
Community Trademark
1
Compliance
1
Confidential Information
1
Conflicting Proposals
1
Copyright
1
Copyright Infringement
1
Corrective Actions
1
Cost-Sharing
1
Counterclaims
1
Counterfeit Drugs
1
Counterfeiting
1
Covenant Not to Sue
1
Covered Business Method Patents
1
Daiichi Sankyo
1
Defect
1
Delaware General Corporation Law
1
Department of Veterans Affairs
1
Device Classification
1
DHS
1
Diagnostic Tests
1
Dietary Supplements
1
Direct Purchasers
1
Disclosure
1
Disclosure Requirements
1
Discovery Rule
1
Disgorgement
1
Doctrine of Equivalents
1
DOHA
1
DOL
1
DQSA
1
EAR
1
EHR
1
Elder Issues
1
Email
1
Employer Mandates
1
Enforcement
1
Evidence Suppression
1
Exceptional Case
1
Excessive Pricing
1
Expert Testimony
1
Exports
1
False Evidence
1
FCPA
1
FD&C Act
1
FDASIA
1
Federal Budget
1
Federal Question Jurisdiction
1
Federal Rule 12(b)(1)
1
Federal Rules of Civil Procedure
1
Fee-for-Service
1
Filing Fees
1
Final Rules
1
First Sale Doctrine
1
Food Labeling
1
Food Recalls
1
Foreign Corporations
1
Foreseeability
1
Forum Shopping
1
Fraudulent Concealment
1
FTEs
1
Generic
1
Genzyme
1
Gilead Sciences
1
Goodyear
1
Government Investigations
1
Grable Factors
1
Health Insurance
1
Health Safety
1
Highmark v. Allcare
1
HIPAA
1
Hoffman LaRoche
1
Home Health Care
1
ICD-10
1
Implied Preemption
1
Imports
1
Information Reports
1
Informed Consent
1
Innovation
1
Inspections
1
International Arbitration
1
International Harmonization
1
International Treaties
1
Inventions
1
Investors
1
IRF Claim Processing
1
Janssen Pharmaceuticals
1
Johnson & Johnson
1
Justiciable Controversy
1
Kickbacks
1
Lanham Act
1
Leave to Amend
1
License Agreements
1
Licenses
1
Long Term Care Facilities
1
Manufacturing Defects
1
Market Manipulation
1
Marketing
1
Medical Foods
1
Medical Research
1
Medicare Modernization Act
1
Method Claims
1
Misrepresentation
1
Mootness
1
Motion for Reconsideration
1
Motion To Centralize
1
Motion to Compel
1
Native American Issues
1
Negligence
1
New Guidance
1
New Legislation
1
New Regulations
1
New Trial
1
Nexus
1
Nike
1
NJ Supreme Court
1
Nominations
1
Non-Grandfathered Health Plans
1
Notice of Intent
1
Notifications
1
Novartis
1
Numerosity
1
Nursing Homes
1
Nutritional Supplements
1
OCR
1
Octane Fitness v. ICON
1
Open Enrollment
1
Opioid
1
OPPS
1
Out-of-State Companies
1
Out-of-State Judgments
1
OxyContin
1
PACE
1
Patent Term Extensions
1
Patent Trial and Appeal Board
1
Patent-Misuse
1
PHSA
1
Physician Fee Schedule
1
Physician Medicare Reimbursements
1
Post-Grant Review
1
Post-Market Approval
1
Prescription Drug Coverage
1
Presidential Elections
1
Price Transparency
1
Price-Fixing
1
Private Right of Action
1
Prometheus
1
Proposed Amendments
1
Proposed Rules
1
Public Meetings
1
Public Performance Rights
1
Public Use
1
Qui Tam
1
RanBaxy
1
Recordkeeping Requirements
1
Registration Requirement
1
Regulatory Standards
1
Renewal Fees
1
Res Ipsa Loquitur
1
Research and Development
1
Restraining Orders
1
Reversal
1
Reverse Payments
1
RICO
1
Risk Management
1
Rule 23
1
Rural Areas
1
Rural Health Care Program
1
SAMHSA
1
Sanofi
1
Section 340B
1
Senate Judiciary Committee
1
Settlement
1
Settlement Agreements
1
Sham Citizen Petitions
1
Sham Litigation Exception
1
Skilled Nursing Facility
1
SmithKline Beecham
1
Social Security
1
Specific Jurisdiction
1
Spoliation
1
Standard of Review
1
State Health Insurance Exchanges
1
State Law Tort Claims
1
Subject Matter Jurisdiction
1
Supply Chain
1
Tax Credits
1
Tobacco Regulations
1
Trade Secrets
1
Trademark Registration
1
Trademark Searches
1
Transvaginal Mesh
1
Two-Midnight Rule
1
U.S. Treasury
1
Uniform Commercial Code (UCC)
1
Universal Health Services Inc v United States ex rel Escobar
1
User Fees
1
Vaccinations
1
Veterans
1
Veterinary Products
1
Warner Chilcott
1
Webinars
1
Whistleblowers
1
WIPO
1
Women's Preventable Healthcare Mandates
1
Work Plans
1
WTO
1
Young Lawyers